Fig. 3: ZMYND8 drives trastuzumab resistance in HER2+ breast cancer in mice.
From: ZMYND8 drives HER2 antibody resistance in breast cancer via lipid control of IL-27
a Growth curve of parental, ZMYND8 KO1 and ZMYND8 KO2 HR6 tumors in mice (n = 5) treated with vehicle (Veh.) or trastuzumab (Tras.). b Immunoblot analysis of ZMYND8 in treated tumors. c, d Growth curve of parental and ZMYND8 overexpressed BT474T tumors in mice (n = 5) treated with vehicle or trastuzumab at the dose of 15 mg/kg (c) or 5 mg/kg (d). e Immunoblot analysis of ZMYND8 in treated tumors. Data from biological replicates represent mean ± SEM. P-value was determined by two-way ANOVA with Tukey’s test (a, c, and d). Source data are provided as a Source Data file.
